Skip to main content

Published locations for FDA approves alectinib as frontline therapy for ALK-positive metastatic NSCLC

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA approves alectinib as frontline therapy for ALK-positive metastatic NSCLC

User login

  • Reset your password
  • /content/fda-approves-alectinib-frontline-therapy-alk-positive-metastatic-nsclc
  • /oncologypractice/article/151516/lung-cancer/fda-approves-alectinib-frontline-therapy-alk-positive
  • /node/155702/article/151516/lung-cancer/fda-approves-alectinib-frontline-therapy-alk-positive
  • /hematology-oncology/article/151516/lung-cancer/fda-approves-alectinib-frontline-therapy-alk-positive
  • /chestphysician/article/151516/lung-cancer/fda-approves-alectinib-frontline-therapy-alk-positive